AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31269801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups assessed at baseline, three and six months after the intervention.
Number of subjects: 30
Study 29929773 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU augmented with TCT
Number of subjects: 46
Study 29929773 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 46
Study 27608342 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 2 FLMA
Number of subjects: 120
Study 27608342 — intervention group
Group type: COMPARATOR
Intervention: Size 2.5 FLMA
Number of subjects: 120
Study 27608342 — intervention group
Group type: EXPERIMENTAL
Intervention: Size 2.5 FLMA in children 16-20 kg
Number of subjects: 120
Study 27608342 — intervention group
Group type: COMPARATOR
Intervention: Size 2 FLMA in children 16-20 kg
Number of subjects: 120
Study 24513849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g XOS
Number of subjects: 32
Study 24513849 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 g XOS
Number of subjects: 32
Study 24513849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22809107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (2,500 Lux) for 1 week
Number of subjects: 28
Study 22809107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 lux) for 1 week
Number of subjects: 28
Study 22809107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (2,500 Lux)
Number of subjects: 28
Study 22809107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 lux)
Number of subjects: 28
Study 21094366 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg and Ezetimibe 10 mg
Number of subjects: 1763
Study 18500187 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg in 10 mL 0.9% normal saline
Number of subjects: 43
Study 18500187 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 10 mL of 0.25%
Number of subjects: 43
Study 15738924 — intervention group
Group type: EXPERIMENTAL
Intervention: MR perfusion measurements using a double-echo FLASH sequence with correction approaches (separating the shortening of T1 and T2*, arterial input function (AIF), and tumor shunts)
Number of subjects: 18
Study 15738924 — intervention group
Group type: EXPERIMENTAL
Intervention: Deconvolution from the AIF
Number of subjects: 18
Study 15738924 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of the AIF
Number of subjects: 18
Study 11704073 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of hydrocortisone
Number of subjects: 2
Study 11704073 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term corticosteroid treatment
Number of subjects: 2
Study 11704073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 9218072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg q.d.s.
Number of subjects: 407
Study 9218072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg b.d.
Number of subjects: 407
Study 7958669 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete amino acid solution containing the dipeptide L‐alanyl‐L‐glutamine (20 g/L)
Number of subjects: 12
Study 7958669 — intervention group
Group type: COMPARATOR
Intervention: Conventional amino acid solution (1.5 g amino acids.kg‐1.day‐1)
Number of subjects: 12
Study 3690031 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 50 mg b.d.
Number of subjects: 20
Study 3690031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30826660 — intervention group
Group type: EXPERIMENTAL
Intervention: PTGS2 (COX‐2) high expression in BRAF-mutated cases
Number of subjects: 1708
Study 30826660 — intervention group
Group type: EXPERIMENTAL
Intervention: PTGS2 (COX‐2) high expression in BRAF-wild-type cases
Number of subjects: 1708
Study 30826660 — intervention group
Group type: EXPERIMENTAL
Intervention: PTGS2 (COX‐2) expression in CALGB/Alliance 89803 trial
Number of subjects: 1708
Study 29976567 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack (emotion-focused intervention)
Number of subjects: 301
Study 29976567 — intervention group
Group type: COMPARATOR
Intervention: KnowIt (educational/behavioral intervention)
Number of subjects: 301
Study 29976567 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack
Number of subjects: 301
Study 29976567 — intervention group
Group type: COMPARATOR
Intervention: KnowIt
Number of subjects: 301
Study 29976567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 301
Study 27010512 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Rehabilitation (VR)
Number of subjects: 61
Study 27010512 — intervention group
Group type: COMPARATOR
Intervention: Control (no VR)
Number of subjects: 61
Study 24619624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreatoduodenectomy (PPPD)
Number of subjects: 100
Study 24619624 — intervention group
Group type: COMPARATOR
Intervention: Subtotal stomach-preserving pancreatoduodenectomy (SSPPD)
Number of subjects: 100
Study 22704366 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular screening based on serum PSA measurements offered to 36,270 men in the screening arm.
Number of subjects: 76813
Study 22704366 — intervention group
Group type: COMPARATOR
Intervention: No screening provided to 40,543 men in the control arm.
Number of subjects: 76813
Study 22704366 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (actual screening).
Number of subjects: 76813
Study 22704366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-screen analysis.
Number of subjects: 76813
Study 22704366 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall follow-up period analysis.
Number of subjects: 76813
Study 22704366 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk reduction.
Number of subjects: 76813
Study 20671376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 82
Study 20671376 — intervention group
Group type: COMPARATOR
Intervention: Other antiplatelet aggregation drugs
Number of subjects: 82
Study 17437729 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline leukocyte counts
Number of subjects: 1268
Study 17437729 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline leukocyte count (in increments of 1,000)
Number of subjects: 1268
Study 17437729 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak creatine phosphokinase
Number of subjects: 1268
Study 17437729 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedure TIMI grade 0 flow
Number of subjects: 1268
Study 17437729 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural TIMI grade 3 flow rates
Number of subjects: 1268
Study 17437729 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial blush grade 2/3
Number of subjects: 1268
Study 15896623 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant MVP (mitomycin C, vinblastin and cisplatin) chemotherapy
Number of subjects: 118
Study 15896623 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 118
Study 11283125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous cytarabine (Ara-C) added to high-dose intravenous methotrexate (MTX)
Number of subjects: 653
Study 11283125 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous methotrexate (MTX) without Ara-C
Number of subjects: 653
Study 11283125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methotrexate (MTX) with Ara-C
Number of subjects: 653
Study 9003857 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrically growth retarded infants (low length-for-age and low weight-for-age)
Number of subjects: 818
Study 9003857 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrically growth retarded infants (normal length-for-age and low weight-for-age)
Number of subjects: 818
Study 9003857 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetric and asymmetric intrauterine growth retarded infants
Number of subjects: 818
Study 9003857 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born short but with normal weight
Number of subjects: 818
Study 9003857 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants with symmetric and asymmetric growth retardation
Number of subjects: 818
Study 9003857 — intervention group
Group type: COMPARATOR
Intervention: Very low birth weight (< or = 1250 gm), gestational age, and broad-based day-care intervention
Number of subjects: 818
Study 8504271 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE) (Prostin E2, 0.5 mg per tablet)
Number of subjects: 60
Study 8504271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8504271 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE)
Number of subjects: 60
Study 8504271 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE) with HSV infection
Number of subjects: 60
Study 3027840 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: 200 mg daily for two consecutive days
Number of subjects: 60
Study 3027840 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: 200 mg twice a day for one day
Number of subjects: 60
Study 3027840 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: 200 mg once a day for three consecutive days
Number of subjects: 60
Study 29848422 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (0.5% proparacaine hydrochloride, pledget soaked, applied 3 minutes before surgery)
Number of subjects: 110
Study 29848422 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia (3 ml of 0.5% bupivacaine, applied 3 minutes before surgery)
Number of subjects: 110
Study 28644357 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (scGOS/lcFOS and B. breve M-16V)
Number of subjects: 30
Study 28644357 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (control)
Number of subjects: 30
Study 25662557 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvogyl
Number of subjects: 60
Study 25662557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (red laser)
Number of subjects: 60
Study 25662557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (infrared laser)
Number of subjects: 60
Study 23517494 — intervention group
Group type: EXPERIMENTAL
Intervention: Care delivered by nurses trained to respond to low complexity problems
Number of subjects: 1461
Study 23517494 — intervention group
Group type: COMPARATOR
Intervention: Usual care delivered by general practitioners
Number of subjects: 1461
Study 21611724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 41
Study 21611724 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride (control)
Number of subjects: 41
Study 18572153 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine A (100, 200, 300, and 400 microg doses, twice daily for a week at each dose)
Number of subjects: 12
Study 18572153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16534770 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of white matter hyperintensities at baseline
Number of subjects: 527
Study 16534770 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of white matter lesion volume
Number of subjects: 527
Study 14697809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and basiliximab (steroid-free)
Number of subjects: 20
Study 14697809 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and steroids (historical control)
Number of subjects: 20
Study 10831926 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded hormone replacement therapy (HRT) doses
Number of subjects: 153
Study 9323077 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug testing guided by electrophysiological study
Number of subjects: 486
Study 9323077 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory ECG monitoring
Number of subjects: 486
Study 9323077 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of arrhythmic deaths/cardiac arrests during follow-up
Number of subjects: 486
Study 9323077 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 486
Study 8436464 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 60
Study 8436464 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (AMX)
Number of subjects: 60
Study 8436464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 60
Study 31747930 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg daily
Number of subjects: 60
Study 31747930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29868706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management
Number of subjects: 2210
Study 29868706 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2210
Study 26921286 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-based recall (text, e-mail, auto-dialer, or 2-methods)
Number of subjects: 867
Study 26921286 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 867
Study 26921286 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for e-mail and phone recall methods
Number of subjects: 867
Study 26921286 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall method (receiving recalls vs not receiving recalls)
Number of subjects: 867
Study 26921286 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall completion rates
Number of subjects: 867
Study 24285642 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive task evaluating fronto-striatal functioning in patients with insomnia
Number of subjects: 0
Study 24285642 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity analysis
Number of subjects: 0
Study 24285642 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful treatment of insomnia
Number of subjects: 0
Study 24285642 — intervention group
Group type: COMPARATOR
Intervention: Slow-wave sleep fragmentation
Number of subjects: 0
Study 22700830 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV-7) administered to all residents in 11 villages.
Number of subjects: 21
Study 22700830 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 villages where only children <30 months old received PCV-7).
Number of subjects: 21
Study 20399326 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide + lifestyle modification program (5 microg twice daily, increased to 10 microg after 4 weeks)
Number of subjects: 194
Study 20399326 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide + lifestyle modification program
Number of subjects: 194
Study 20399326 — intervention group
Group type: COMPARATOR
Intervention: Placebo + lifestyle modification program
Number of subjects: 194
Study 17943589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient‐controlled analgesia (IV‐PCA)
Number of subjects: 31
Study 17943589 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular analgesics (meperidine)
Number of subjects: 31
Study 15996029 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 60
Study 15996029 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 11991427 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with reassurance, a well-fitted brassiere, caffeine reduction, and primrose oil
Number of subjects: 0
Study 11991427 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications such as danazol, bromocriptine, and tamoxifen
Number of subjects: 0
Study 11991427 — intervention group
Group type: COMPARATOR
Intervention: Future studies should include selective-serotonin reuptake inhibitors and primrose oil
Number of subjects: 0
Study 11991427 — intervention group
Group type: COMPARATOR
Intervention: Caffeine reduction
Number of subjects: 0
Study 10609970 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisconsin Smoking Withdrawal Scale
Number of subjects: 163
Study 8609339 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angioplasty
Number of subjects: 127
Study 8609339 — intervention group
Group type: COMPARATOR
Intervention: Bypass Surgery
Number of subjects: 127
Study 1930766 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter‐accompanied exercise (walking)
Number of subjects: 30
Study 1930766 — intervention group
Group type: COMPARATOR
Intervention: Social contact control condition
Number of subjects: 30
Study 1930766 — intervention group
Group type: COMPARATOR
Intervention: Wait‐list control
Number of subjects: 30
Study 6756707 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50mg q.i.d./3 days)
Number of subjects: 48
Study 6756707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (1 mg)
Number of subjects: 48
Study 6756707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid (250 mg)
Number of subjects: 48
Study 6756707 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (100mg) in renovascular patients
Number of subjects: 48
Study 6756707 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25mg b.i.d./3 days) in essential hypertensive patients
Number of subjects: 48
Study 6756707 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily/6 days)
Number of subjects: 48
Study 31664728 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual pedagogy and video modeling with yoga
Number of subjects: 72
Study 31664728 — intervention group
Group type: COMPARATOR
Intervention: Visual pedagogy and video modeling
Number of subjects: 72
Study 27928636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 46
Study 27928636 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 46
Study 25414430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1600 IU and calcium carbonate 1000 mg (D+)
Number of subjects: 150
Study 25414430 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate alone (D-)
Number of subjects: 150
Study 25414430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (D+ and D-)
Number of subjects: 150
Study 23662292 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg gabapentin
Number of subjects: 50
Study 23662292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21493417 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 50 µg/kg
Number of subjects: 90
Study 21493417 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 75 µg/kg
Number of subjects: 90
Study 21493417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 21493417 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 50 µg/kg and Midazolam 75 µg/kg
Number of subjects: 90
Study 19458163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methotrexate (MTX) and sulfasalazine (SSZ) in patients naïve to both drugs
Number of subjects: 4
Study 19458163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methotrexate (MTX) and sulfasalazine (SSZ) in patients who previously failed SSZ
Number of subjects: 4
Study 19458163 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ) alone in patients who previously failed SSZ
Number of subjects: 4
Study 19458163 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone in patients naïve to both drugs
Number of subjects: 4
Study 17928776 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg, dosage may be doubled if BP >= 140/90 mmHg, duration 8-12 weeks
Number of subjects: 702
Study 17928776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during 2-4 weeks run-in period)
Number of subjects: 702
Study 15186866 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience-based group educational programme (pharmacist-led, year-long intervention)
Number of subjects: 77
Study 15186866 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience-based group educational programme
Number of subjects: 77
Study 11965096 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic students (boys)
Number of subjects: 2926
Study 11965096 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic students (girls)
Number of subjects: 2926
Study 11965096 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic students (boys) practicing individual 'X‐treme' sport
Number of subjects: 2926
Study 11965096 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic students (boys) practicing collective or non‐'X‐treme' sport
Number of subjects: 2926
Study 11965096 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic students
Number of subjects: 2926
Study 11965096 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic students who practiced sport for seeking emotions
Number of subjects: 2926
Study 11965096 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic students who did not practice sport for health benefits
Number of subjects: 2926
Study 9624938 — intervention group
Group type: EXPERIMENTAL
Intervention: Room temperature alcohol swabs
Number of subjects: 53
Study 9624938 — intervention group
Group type: COMPARATOR
Intervention: Pinprick
Number of subjects: 53
Study 7530438 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) concentration method
Number of subjects: 50
Study 3292487 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiation plus microwave hyperthermia (RT + Ht)
Number of subjects: 44
Study 3292487 — intervention group
Group type: COMPARATOR
Intervention: Radical radiation (RT)
Number of subjects: 44
Study 28939004 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000mg daily plus prednisone 10mg daily
Number of subjects: 1088
Study 28939004 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 10mg daily
Number of subjects: 1088
Study 28939004 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 1088
Study 28249119 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL blueberry concentrate providing 387 mg anthocyanidins
Number of subjects: 12
Study 28249119 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic placebo
Number of subjects: 12
Study 25129453 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer adherence support (PAS)
Number of subjects: 294